Technological discontinuities and the nature of competition

Technology Analysis and Strategic Management

Volumn 12, Issue 2, 2000, Pages 149-160

  Rothaermel, Frank T ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH TECHNOLOGY INDUSTRY; INDUSTRIAL COMPETITION; INNOVATION; PHARMACEUTICAL INDUSTRY;

EID: 0034073580     PISSN: 09537325     EISSN: None     Source Type: Journal    
DOI: 10.1080/713698467     Document Type: Article

References (55)

1. J. A. Schumpeter, Capitalism, Socialism and Democracy (New York, Harper & Row, 1942), p. 83.
2. Ibid., pp. 83-84.
3. K. B. Lee & G. S. Burrill, Biotech '95: Reform, Restructure, Renewal (Palo Alto, CA, Ernst & Young, LLP, 1994).
4. N. P. Greis, M. D. Dibner & A. S. Bean, 'External Partnering as a Response to Innovation Barriers and Global Competition in Biotechnology', Research Policy, 24, 1995, pp. 609-630. G. P. Pisano, 'The Governance of Innovation: Vertical Integration and Collaborative Arrangements in the Biotechnology Industry', Research Policy, 20, 1991, pp. 237-249.
5. N. P. Greis, M. D. Dibner & A. S. Bean, 'External Partnering as a Response to Innovation Barriers and Global Competition in Biotechnology', Research Policy, 24, 1995, pp. 609-630. G. P. Pisano, 'The Governance of Innovation: Vertical Integration and Collaborative Arrangements in the Biotechnology Industry', Research Policy, 20, 1991, pp. 237-249.
6. E. Ehrnberg & N. Sjöberg, 'Technological Discontinuities, Competition and Firm Performance', Technology Analysis & Strategic Management, 7, 1995, pp. 93-107.
7. Schumpeter, op. cit., Ref. 1.
8. M. D. McKelvey, 'Discontinuities in Genetic Engineering for Pharmaceuticals? Firm Jumps and Lock-in in Systems of Innovation', Technology Analysis & Strategic Management, 8, 1996, pp. 107-116.
9. D. J. Teece, 'Profiting from Technological Innovation: Implications for Integration, Collaboration, Licensing and Public Policy', Research Policy, 15, 1985, pp. 285-305.
10. W. Mitchell, 'Are More Good Things Better, or Will Technical and Market Capabilities Conflict when a Firm Expands?, Industrial and Corporate Change, 1, 1992, pp. 327-346.
11. M. Tripsas, 'Unraveling the Process of Creative Destruction: Complementary Assets and Incumbent Survival in the Typesetter Industry', Strategic Management Journal, 18, 1997, pp. 119-142.
12. F. T. Rothaermel, 'Creative Destruction' or 'Creative Cooperation'? An Empirical Investigation of Technological Discontinuities and their Effect on the Nature of Competition and Firm Performance, Unpublished PhD dissertation, University of Washington, 1999.
13. K. Pavitt, 'Technologies, Products, and Organization in the Innovating Firm: What Adam Smith Tells Us and Joseph Schumpeter Doesn't', Industrial and Corporate Change, 7, 1998, pp. 433-452.
14. M. E. Porter, Competitive Advantage. Creating and Sustaining Superior Performance (New York, Free Press, 1985).
15. M. L. Tushman & P. Anderson, 'Technological Discontinuities and Organizational Environments', Administrative Science Quarterly, 31, 1986, pp. 439-465.
16. F. T. Rothaermel, 'Creative Destruction or Creative Cooperation? A Tale of Two Industries', in: M. A. Hitt, P. G. Clifford, R. D. Nixon & K. Coyne (Eds), Dynamic Strategic Resources: Development, Diffusion, and Integration (New York, John Wiley, 1999), pp. 245-266.
17. Mitchell, op. cit., Ref. 9; Pavitt, op. cit., Ref. 12; Tripsas, op. cit., Ref. 10.
18. Mitchell, op. cit., Ref. 9; Pavitt, op. cit., Ref. 12; Tripsas, op. cit., Ref. 10.
19. Mitchell, op. cit., Ref. 9; Pavitt, op. cit., Ref. 12; Tripsas, op. cit., Ref. 10.
20. Pavitt, op. cit., Ref. 12.
21. Schumpeter, op. cit., Ref. 1.
22. Tushman & Anderson, op. cit., Ref. 14.
23. D. Leonard-Barton, 'Core Capabilities and Core Rigidities: A Paradox in Managing New Product Development', Strategic Management Journal, 13, 1992, pp. 111-125.
24. Schumpeter, op. cit., Ref. 1.
25. Tushman & Anderson, op. cit., Ref. 14.
26. Mitchell, op. cit., Ref. 9; Pavitt, op. cit., Ref. 12; Tripsas, op. cit., Ref. 10.
27. Mitchell, op. cit., Ref. 9; Pavitt, op. cit., Ref. 12; Tripsas, op. cit., Ref. 10.
28. Mitchell, op. cit., Ref. 9; Pavitt, op. cit., Ref. 12; Tripsas, op. cit., Ref. 10.
29. Teece, op. cit., Ref. 8.
30. W. J. Abernathy & K. B. Clark, 'Innovation: Mapping the Winds of Creative Destruction', Research Policy, 14, 1985, pp. 3-22.
31. Teece, op cit., Ref. 8.
32. A. Stinchcombe, 'Social Structure and Organization', in: J. G. March (Ed.), Handbook of Organizations (Chicago, Rand McNally, 1965), pp. 142-193.
33. Pisano, op. cit., Ref. 4.
34. Rothaermel, op cit., Ref. 11.
35. It is important to note that most drug discovery and development today is still based on synthetic organic chemistry. Only a few, albeit important for industry for performance, 'pure' biotechnology drugs, i.e. recombinant proteins, have reached the market for pharmaceuticals.
36. R. Teitelman, Gene Dreams. Wall Street, Academia, and the Rise of Biotechnology (New York, Basic Books, 1989).
37. M. D. McKelvey, Evolutionary Innovations. The Business of Biotechnology (Oxford, University Press, 1996).
38. Lee & Burrill, op. cit., Ref. 3.
39. Greis et al., op cit., Ref. 4.
40. K. B. Lee & G. S. Burrill, Biotech '97: Alignment (Palo Alto, CA, Ernst & Young, LLP, 1996).
41. J. Hagedoorn, 'Understanding the Rationale of Strategic Technology Partnering: Interorganizational Modes of Cooperation and Sectoral Differences', Strategic Management Journal, 14, 1993, pp. 371-385.
42. K. R. Harrigan, Strategies for Joint Ventures (Lexington, MA, Lexington Books, 1985).
43. A. Arora & A. Gambardella, 'Complementarity and External Linkages: The Strategies of the Large Firms in Biotechnology', Journal of Industrial Economics, 4, 1990, 361-379.
44. A. Gambardella, Science and Innovation. The US Pharmaceutical Industry During the 1980s (Cambridge, UK, Cambridge University Press, 1995).
45. Lee & Burrill, op. cit., Ref. 35; Scrip's 1998 Yearbook, Vol. 1 (PJB Publications, 1998).
46. Lee & Burrill, op. cit., Ref. 35; Scrip's 1998 Yearbook, Vol. 1 (PJB Publications, 1998).
47. Pisano, op. cit., Ref. 4.
48. L. G. Zucker & M. R. Darby, 'Present at the Biotechnology Revolution: Transformation of Technological Identity for a Large Incumbent Pharmaceutical Firm', Research Policy, 26, 1997, 429-446.
49. K. B. Lee & G. S. Burrill, Biotech'96: Pursuing Sustainability (Palo Alto, CA, Ernst & Young, LLP, 1995).
50. Abernathy & Clark, op. cit., Ref. 25.
51. Ibid.
52. Tripsas, op. cit., Ref. 10.
53. Mitchell, op. cit., Ref. 9.
54. R. M. Henderson & K. B. Clark, 'Architectural Innovation: The Reconfiguration of Existing Product Technologies and the Failure of Established Firms', Administrative Science Quarterly, 35, 1990, pp. 9-30.
55. C. M. Christensen, The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail (Boston, MA, Harvard Business School Press, 1997).